Kenvue Inc. (NYSE:KVUE) Receives Average Rating of “Hold” from Analysts

Kenvue Inc. (NYSE:KVUE) has earned an average recommendation of “Hold” from the thirteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $24.42.

Several brokerages have commented on KVUE. Redburn Atlantic began coverage on shares of Kenvue in a research report on Thursday. They issued a “neutral” rating and a $23.50 price target for the company. Piper Sandler raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. UBS Group decreased their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Canaccord Genuity Group lifted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th.

Hedge Funds Weigh In On Kenvue

Large investors have recently bought and sold shares of the stock. Grove Bank & Trust boosted its stake in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue in the fourth quarter valued at about $29,000. SRS Capital Advisors Inc. raised its holdings in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after buying an additional 571 shares during the last quarter. Fortitude Family Office LLC raised its holdings in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after buying an additional 1,441 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 0.5 %

Kenvue stock opened at $21.89 on Friday. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a 50 day moving average price of $22.62 and a 200 day moving average price of $22.41. The company has a market capitalization of $41.83 billion, a PE ratio of 41.30, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Research analysts expect that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.75%. Kenvue’s dividend payout ratio is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.